The company also announced the resignation of John Radak as VP for finance and principal accounting officer, effective Jan. 31. He will be replaced by Kelli Richard, who has been corporate controller at Invitrogen since August 2005.
Ben Bowen, William Albright, Ben Bulkley, Bernd Brust, John Radak, Kelli Richard
Ben Bowen has been appointed vice president of business development at Biolog.
Bowen will be responsible for launching Biolog’s forthcoming mammalian cell Phenotype Microarray product. Previously, Bowen served as vice president of discovery research at Lynx Therapeutics. He has also worked at Pioneer Hi-Bred (now part of DuPont).
ForteBio this week named William Albright as the company’s chief financial officer.
Albright most recently served as chief financial officer and senior vice president of finance and operations at Xenogen, now part of Caliper Life Sciences. He has also held executive positions at FlowMedica, Nexell Therapeutics, LocalMed, Connectics, and ChemTrak. He holds an MBA from Harvard Business School, and a BS and MS in biology from StanfordUniversity.
Ben Bulkley and Invitrogen have mutually agreed for his departure from the company, Invitrogen said in a document filed with the US Securities and Exchange Commission this week. Bulkley is senior vice president of commercial operations. His departure date is Jan. 31. Bernd Brust, senior vice president of global sales, will replace him.